Stojkovski, Igor

Preferred name
Stojkovski, Igor
Official Name
Stojkovski, Igor
Translated Name
Стојковски Игор
Alternative Name
Stojkovski I.
I. Stojkovski
Main Affiliation
Email
istojkovski@gmail.com
Scopus Author ID
0000-0002-5770-2578
Researcher ID
N-2436-2018

Settings

Now showing 1 - 10 of 58
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Prognostic factors in patients with recurrent head and neck cancer treated with reirradiation
    (2008)
    ;
    Tolevska, C
    ;
    ;
    ;
    The aim of this study was to determine the prognostic factors concerning overall survival (OS) and progression- free survival (PFS) following reirradiation in patients with recurrent squamous cell head and neck cancer (HNC).
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency
    (2011-03-01)
    Nagata, Yasushi
    ;
    Wulf, Joern
    ;
    Lax, Ingmar
    ;
    Timmerman, Robert
    ;
    Zimmermann, Frank
    To evaluate the current status of stereotactic body radiotherapy (SBRT) and identify both advantages and disadvantages of its use in developing countries, a meeting composed of consultants of the International Atomic Energy Agency was held in Vienna in November 2006. Owing to continuous developments in the field, the meeting was extended by subsequent discussions and correspondence (2007-2010), which led to the summary presented here. The advantages and disadvantages of SBRT expected to be encountered in developing countries were identified. The definitions, typical treatment courses, and clinical results were presented. Thereafter, minimal methodology/technology requirements for SBRT were evaluated. Finally, characteristics of SBRT for developing countries were recommended. Patients for SBRT should be carefully selected, because single high-dose radiotherapy may cause serious complications in some serial organs at risk. Clinical experiences have been reported in some populations of lung cancer, lung oligometastases, liver cancer, pancreas cancer, and kidney cancer. Despite the disadvantages expected to be experienced in developing countries, SBRT using fewer fractions may be useful in selected patients with various extracranial cancers with favorable outcome and low toxicity.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Availability of technology for managing cancer patients in the Southeast European (SEE) region
    (Elsevier BV, 2022-03)
    Dosanjh, Manjit
    ;
    ;
    ;
    Georgieva, Petya
    ;
    Balin Kovacevic, Marijana
    Background: The Southeast European (SEE) region of 10 countries and about 43 million people differs from Western Europe in that most SEE countries lack active cancer registries and have fewer diagnostic imaging devices and radiotherapy (RT) units. The main objective of this research is to initiate a common platform for gathering SEE regional cancer data from the ground up to help these countries develop common cancer management strategies. Methods: To obtain detailed on-the-ground information, we developed separate questionnaires for two SEE groups: a) ONCO - oncologists regarding cancer treatment modalities and the availability of diagnostic imaging and radiotherapy equipment; and b) REG - national radiation protection and safety regulatory bodies regarding diagnostic imaging and radiotherapy equipment in SEE facilities. Results: Based on responses from 13/17 ONCO participants (at least one from each country) and from 9/10 REG participants (all countries but Albania), cancer incidence rates are higher in those SEE countries that have greater access to diagnostic imaging equipment while cancer mortality-to-incidence (MIR) ratios are higher in countries that lack radiotherapy equipment. Conclusion: By combining unique SEE region information with data available from major global databases, we demonstrated that the availability of diagnostic imaging and radiotherapy equipment in the SEE countries is related to their economic development. While immediate diagnostic imaging and radiation therapy capacity building is necessary, it is also essential to develop both national and SEE-regional cancer registries in order to understand the heterogeneity of each country’s needs and to establish regional collaborative strategies for combating cancer.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    A review of the International Early Recommendations for Departments Organization and Cancer Management Priorities during the Global COVID-19 Pandemic. Applicability in Low- and Middle-Income Countries
    (Elsevier BV, 2020-06)
    Belkacemi, Yazid
    ;
    Grellier, Noemie
    ;
    Ghith, Sahar
    ;
    Debbi, Kamel
    ;
    Coraggio, Gabriele
    Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low and middle income countries (LMICs). In this review we aimed to summarize these international guidelines according to cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumor criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    An Update on Access to Novel Treatment for Metastatic Melanoma in Europe — A 2024 Survey of the European Melanoma Registry and the European Association of Dermato-Oncology
    (Elsevier BV, 2024-11)
    Kandolf, L
    ;
    Ascierto, P
    ;
    Bastholt, L
    ;
    Gavrilova, I
    ;
    Haanen, J
    Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25% of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48%, 63%, and 37% in 2017 to 96%, 96%, and 78% in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48% of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 12 countries and talimogene laherpervec in 6. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 16 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan)
    (2019)
    Todorovic, Vladimir
    ;
    Aapro, Matti
    ;
    Pavlidis, Nicholas
    ;
    Arsovski, Oliver
    ;
    Belkacemi, Yazid
    PURPOSE: Cancer is a leading cause of mortality worldwide. Its incidence is still increasing, particularly in developing countries. Recent progresses further strengthen the differences between low/middle and high-income countries. This situation calls for joint action to reduce inequities in cancer outcomes among the patients. The Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) and the European School of Oncology (ESO), have initiated joint conferences devoted to access to innovations in oncology in the Mediterranean area. The heterogeneity of the economic, political and cultural situations of the different participating countries, offers the opportunity to develop consensus conference. METHODS: Cancer prevention and treatment strategies were discussed according to existing international guidelines. The Scientific committee prepared 111 questions with an objective to prioritize the access to treatments and innovations in low/middle-income Mediterranean countries. The results from the votes of 65 oncology experts, coming from 16 countries and 33 institutions have been analysed and access priorities classified accordingly. RESULTS: Ninety six percent of the proposed general recommendations concerning national health care strategies, oncology education, and treatment organization were considered to be high priorities. Regarding access to systemic treatments, 41% of the drugs without validated predictive markers and 53% of those with validated predictive markers were considered to be 1st level priority. Only 4 biological tests were considered to be 1st level priority to access to innovation. CONCLUSIONS: AROME-ESO consensus offers to cancer specialists from developing countries a basis for discussion with health authorities and payers on the prioritization of access to innovations in cancer care.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Radical radiotherapy for squamous cell carcinoma of the larynx - comparison of three-dimensional conformal radiotherapy with cobalt-60 teletherapy
    (2011)
    ;
    ;
    The aim of the study was to report the results of radical radiotherapy performed by three-dimensional conformal radiotherapy (3DCRT) for squamous cell carcinoma of the larynx and to compare these data with those obtained with two-dimensional radiotherapy (2DRT) realized with cobalt-60 teletherapy i.e. telecobalt therapy (TCT). Eighty patients with previously untreated laryngeal cancer were irradiated with curative intent at the University of Radiotherapy and Oncology Clinic (UCRO) in Skopje between February 1999 and December 2008. Radical radiotherapy with the TCT unit was performed on 38 patients between February 1999 and May 2005. From June 2005 to December 2008, 42 patients were treated with a linear accelerator using 3DCRT. Complete response rates three months after completion of radiotherapy were 84.2% (32 of 38) and 92.6% (39 of 42) in the group irradiated with TCT unit and in the group treated with 3DCRT, respectively. No statistically significant differences were observed either in locoregional control (LRC) or overall survival (OS) between the patients treated with two different radiotherapy techniques. The grade of acute reactions of the skin and the larynx differed significantly between the accomplished radiotherapy techniques (Nonparametric Mann-Whitney U Test; U=577.0; Z=-2.129; p=0.012, and U=497.0; Z=-2.90; p=0.001, respectively). There were statistically significant differences observed in the grade of late effects in the skin and in the subcutaneous tissue between the radiotherapy techniques used (Nonparametric Mann-Whitney U Test; U=425.0; Z=-3.593; p=0.001 and U=637.0; Z=-1.551; p=0.035, respectively). According to the confirmed advantage of 3DCRT in terms of reduced treatment toxicity observed in our study, we consider conformal techniques being a basis in definitive radiotherapy of squamous cell carcinoma of the larynx until the new revolutionary techniques will be clinically available.